康柏西普联合玻璃体切除术治疗进展型糖尿病性视网膜病变的临床疗效及对患者血清学指标与视力水平及生命质量的影响

Clinical efficacy of conbercept combined with pars plana vitrectomy in the treatment of progressive diabetic retinopathy and its effect on serological indexes and visual acuity and quality of life of patients

目的探究康柏西普联合玻璃体切除术(PPV)治疗进展型糖尿病性视网膜病变(DR)对患者血清学指标、视力水平及生命质量的影响。方法选取2020年7月至2022年7月菏泽市立医院收治的70例进展型DR患者作为研究对象,按照随机数字表法分为A组与B组,每组35例。A组行PPV治疗,B组行PPV联合康柏西普治疗,比较两组血清学指标[血管内皮细胞生长因子(VEGF)、胎盘生长因子(PIGF)]、视力水平[最佳矫正视力(BCVA)、黄斑中心凹厚度(CMT)]、并发症发生率及生命质量。结果治疗后1、3个月,两组VEGF、PIGF水平均低于前一时间点,且B组低于A组,差异有统计学意义(P<0.05)。治疗后1、3个月,两组BCVA水平均高于前一时间点,CMT水平均薄于前一时间点,且B组BCVA水平高于A组,CMT水平薄于A组,差异有统计学意义(P<0.05)。B组并发症发生率为11.43%,低于A组的34.29%,差异有统计学意义(P<0.05)。治疗后,两组总体健康、总体视力、眼痛、近距离视力、远距离视力、驾车、周边视力(视野)、视觉相关社会角色限制、依赖程度、社会功能、精神健康评分及总分均高于治疗前,且B组高于A组,差异有统计学意义(P<0.05),两组色觉评分比较差异无统计学意义。结论PPV联合康柏西康治疗进展型DR理想,可改善血清学指标及视力水平,提高患者生命质量,且安全性较高。

Objective To explore the effect of conbercept combined with pars plana vitrectomy(PPV)in the treatment of progressive diabetic retinopathy(DR)and its effect on serological indexes,visual acuity and quality of life of patients.Methods 70 patients with progressive DR admit-ted to Heze Municipal Hospital from July 2020 to July 2022 were selected as the research subjects,and they were randomly divided into the group A and the group B according to the random number table method,with 35 cases in each group.The group A was treated with PPV,and the group B was treated with PPV combined with conbercept,the serological indexes(vascular endothelial growth factor[VEGF],placental growth factor[PIGF]),vi-sual acuity(best corrected visual acuity[BCVA],central macular thickness[CMT]),incidence of complications and quality of life were compared be-tween the two groups.Results At 1 and 3 months after treatment,the levels of VEGF and PIGF of the two groups were lower than those at the previ-ous time point,and the group B was lower than the group A,the differences were statistically significant(P<0.05).At 1 and 3 months after treat-ment,the BCVA levels of the two groups were higher than those at the previous time point,and the CMT levels were lower than those at the previous time point,the BCVA level in the group B was higher than that in the group A,and the CMT level was lower than that in the group A,the differences were statistically significant(P<0.05).The incidence of complications in the group B was 11.43%,which was lower than 34.29%in the group A,and the difference was statistically significant(P<0.05).After treatment,the overall health,overall vision,eye pain,near vision,long-distance vi-sion,driving,peripheral vision(visual field),visual related social role limitation,dependence,social function,mental health score and total score of the two groups were higher than those before treatment,and the group B as higher than the group A,the difference was statistically significant(P<0.05),there was no significant difference in color vision score between the two groups.Conclusion PPV combined with conbercept is ideal for the treatment of progressive DR,which can improve serological indicators and visual acuity,improve the quality of life of patients,and has high safety.